Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TNFA TNF Pharmaceuticals Inc.
- Stocks
- Healthcare
- NASDAQ: TNFA
Price (delayed)
$0.1228
Market cap
$1.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.67
Enterprise value
$1.67M
mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage
Highlights
The company's debt has shrunk by 93% YoY and by 75% QoQ
The EPS has grown by 40% from the previous quarter and by 30% YoY
The quick ratio has soared by 170% YoY but it fell by 6% QoQ
The company's net income rose by 37% QoQ but it fell by 19% YoY
TNF Pharmaceuticals's equity has decreased by 13% YoY and by 11% QoQ
Key stats
What are the main financial stats of TNFA
Market
Valuations
Earnings
Shares outstanding
14.18M
Market cap
$1.74M
Enterprise value
$1.67M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.04
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$9.86M
Net income
-$14.68M
EBIT
-$14.68M
EBITDA
-$14.68M
Free cash flow
-$9.7M
Per share
Balance sheet
Liquidity
EPS
-$6.67
EPS diluted
-$6.67
Free cash flow per share
-$1.81
Book value per share
$3.15
Revenue per share
$0
TBVPS
$1.55
Total assets
$18.78M
Total liabilities
$4.94M
Debt
$2,678
Equity
$8.69M
Working capital
$1.84M
Debt to equity
0
Current ratio
1.37
Quick ratio
1.19
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-79.9%
Return on equity
-204.7%
Return on invested capital
-263.3%
Return on capital employed
-106.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNFA stock price
How has the TNF Pharmaceuticals stock price performed over time
Intraday
-5.54%
1 week
-11.01%
1 month
-23.44%
1 year
-93.33%
YTD
-89.32%
QTD
-64.91%
Financial performance
How have TNF Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.86M
Net income
-$14.68M
Gross margin
N/A
Net margin
N/A
TNFA's operating income is up by 43% year-on-year and by 3.1% since the previous quarter
The company's net income rose by 37% QoQ but it fell by 19% YoY
Price vs fundamentals
How does TNFA's price correlate with its fundamentals
Growth
What is TNF Pharmaceuticals's growth rate over time
Valuation
What is TNF Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 40% from the previous quarter and by 30% YoY
The stock's P/B is 100% below its last 4 quarters average of 11.0 and 99% below its 5-year quarterly average of 5.9
TNF Pharmaceuticals's equity has decreased by 13% YoY and by 11% QoQ
Efficiency
How efficient is TNF Pharmaceuticals business performance
TNFA's ROIC is up by 47% since the previous quarter and by 7% year-on-year
TNF Pharmaceuticals's return on equity has decreased by 42% YoY but it has increased by 31% QoQ
The ROA has grown by 36% from the previous quarter and by 10% YoY
Dividends
What is TNFA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNFA.
Financial health
How did TNF Pharmaceuticals financials performed over time
The quick ratio has soared by 170% YoY but it fell by 6% QoQ
The current ratio has soared by 121% year-on-year but it has declined by 2.1% since the previous quarter
The company's debt is 100% lower than its equity
The company's debt has shrunk by 93% YoY and by 75% QoQ
TNF Pharmaceuticals's equity has decreased by 13% YoY and by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.